Sichuan Kelun Pharmaceutical Research Institute Co., Ltd.

Country

Ownership: Private

Employees: -

Market Cap: -

Website

Clinical Trials

SKB264 Monotherapy in Selected Subjects With Advanced Solid Tumors

Phase 2

Recruiting

Conditions: Selected Subjects With Advanced Solid Tumors

Interventions: Drug: SKB264
Drug: Docetaxel

First Posted Date: 2022-11-30

Last Posted Date: 2023-10-24

Lead Sponsor: Sichuan Kelun Pharmaceutical Research Institute Co., Ltd.

Target Recruit Count: 366

Registration Number: NCT05631262

Locations: 🇨🇳
Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China

A Study of Intratumoral KL340399 in Patients with Advanced Solid Tumors

Phase 1

Recruiting

Conditions: Advanced Solid Tumors

Interventions: Drug: KL340399 Intratumoral

First Posted Date: 2022-09-22

Last Posted Date: 2024-12-09

Lead Sponsor: Sichuan Kelun Pharmaceutical Research Institute Co., Ltd.

Target Recruit Count: 30

Registration Number: NCT05549804

Locations: 🇨🇳
Beijing Cancer Hospital, Beijing, Beijing, China

A Study of KL130008 in Adults With Severe Alopecia Areata

Phase 2

Not yet recruiting

Conditions: Alopecia Areata

Interventions: Drug: KL130008/Placebo

First Posted Date: 2022-08-11

Last Posted Date: 2022-08-11

Lead Sponsor: Sichuan Kelun Pharmaceutical Research Institute Co., Ltd.

Target Recruit Count: 176

Registration Number: NCT05496426

Locations: 🇨🇳
The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, Guangzhou, China

A Study of KL340399 in Patients With Advanced Solid Tumors

Phase 1

Recruiting

Conditions: Advanced Solid Tumors

Interventions: Drug: KL340399 injection

First Posted Date: 2022-05-24

Last Posted Date: 2024-06-27

Lead Sponsor: Sichuan Kelun Pharmaceutical Research Institute Co., Ltd.

Target Recruit Count: 30

Registration Number: NCT05387928

Locations: 🇨🇳
Beijing Cancer Hospital, Beijing, Beijing, China

A Study of SKB315 in Patients With Advanced Solid Tumors

Phase 1

Recruiting

Conditions: Advanced Solid Tumors

Interventions: Drug: SKB315 for injection

First Posted Date: 2022-05-10

Last Posted Date: 2023-10-24

Lead Sponsor: Sichuan Kelun Pharmaceutical Research Institute Co., Ltd.

Target Recruit Count: 206

Registration Number: NCT05367635

Locations: 🇨🇳
Tianjin Medical University Cancer Institute & Hospital, Tianjin, Tianjin, China

SKB264 Combinatiton Therapy in Patients With Advanced or Metastatic Non-small Cell Lung Cancer.

Phase 2

Recruiting

Conditions: Non-small Cell Lung Cancer

Interventions: Drug: SKB264
Drug: KL-A167
Drug: Carboplatin
Drug: Cisplatin

First Posted Date: 2022-04-28

Last Posted Date: 2023-12-14

Lead Sponsor: Sichuan Kelun Pharmaceutical Research Institute Co., Ltd.

Target Recruit Count: 110

Registration Number: NCT05351788

Locations: 🇨🇳
Sun Yat-sen University Cancer Center, Guangzhou, China

SKB264 Injection Vs Investigator Selected Regimens to Treat Locally Advanced, Recurrent or Metastatic Triple-negative Breast Cancer

Phase 3

Active, not recruiting

Conditions: Triple Negative Breast Cancer

Interventions: Drug: SKB264

First Posted Date: 2022-04-26

Last Posted Date: 2024-12-12

Lead Sponsor: Sichuan Kelun Pharmaceutical Research Institute Co., Ltd.

Target Recruit Count: 254

Registration Number: NCT05347134

Locations: 🇨🇳
Cancer Hospital Chinese Academy of Medical Science, Beijing, Beijing, China
🇨🇳
Jiangsu Province Hospital, Nanjing, Jiangsu, China

A Study of KL590586 in Patients With Advanced Solid Tumors

Phase 1

Active, not recruiting

Conditions: Advanced Solid Tumor

Interventions: Drug: KL590586 Capsule

First Posted Date: 2022-03-03

Last Posted Date: 2024-06-25

Lead Sponsor: Sichuan Kelun Pharmaceutical Research Institute Co., Ltd.

Target Recruit Count: 414

Registration Number: NCT05265091

Locations: 🇨🇳
Sichuan Kelun Botai Biopharmaceutical Co., Chengdu, Sichuan, China

Comparison of A140 and Erbitux Combined With mfolfox6 to Evaluate Efficacy and Safety of First-line Treatment for Ras Wild-type mCRC

Phase 3

Completed

Conditions: Metastatic Colorectal Cancer

Interventions: Drug: Open single period A140
Drug: Double blind control period A140

First Posted Date: 2021-04-08

Last Posted Date: 2024-08-05

Lead Sponsor: Sichuan Kelun Pharmaceutical Research Institute Co., Ltd.

Target Recruit Count: 688

Registration Number: NCT04835142

Locations: 🇨🇳
307 Hospital of PLA, Beijing, Beijing, China

Epidermal Growth Factor Receptor (EGFR) Antagonist Chimeric Anti-EGFR Monoclonal Antibody Trial

Phase 3

Conditions: Metastatic Colorectal Cancer

Interventions: Drug: KL-140
Drug: Placebo

First Posted Date: 2018-02-08

Last Posted Date: 2018-02-08

Lead Sponsor: Sichuan Kelun Pharmaceutical Research Institute Co., Ltd.

Target Recruit Count: 570

Registration Number: NCT03426371

Locations: 🇨🇳
307 Hospital of PLA, Beijing, Beijing, China

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy